June 26, 2015
Consumers and health plans who filed pay-for-delay litigation over Cephalon Inc.'s narcolepsy drug Provigil asked a Pennsylvania federal judge Thursday to reconsider his decision not to certify them as a class, contending the court made several key errors.
June 11, 2015
A Pennsylvania federal judge on Wednesday explained that his recent refusal to let consumers and health plans go forward with class antitrust pay-for-delay claims against Cephalon Inc. and four generic drugmakers stemmed from concerns that the plaintiffs had no way to ascertain who the class members were.
June 02, 2015
A Pennsylvania federal judge on Monday refused to certify a class of health plans and others that ultimately paid for narcolepsy drug Provigil in an antitrust suit against Cephalon Inc., days after the drugmaker settled similar pay-for-delay claims with the Federal Trade Commission for $1.2 billion.
June 23, 2014
A Pennsylvania federal judge ruled on Monday that Apotex Inc. and Provigil buyers could not prove that reverse payment patent settlements Cephalon Inc. inked with four generic-drug makers amounted to a conspiracy among the defendants to keep cheaper versions of the narcolepsy drug off the market.
September 24, 2013
The Federal Trade Commission asked a Pennsylvania federal judge Friday to bar Cephalon Inc. from discussing the validity of its patent for narcolepsy drug Provigil at trial, pointing to a recent U.S. Supreme Court ruling that held the issue of patent validity needn't be addressed in antitrust cases.
August 30, 2012
A judge overseeing a long-running pay-for-delay dispute brought by the Federal Trade Commission and others against Cephalon Inc. stayed the cases Wednesday over the objections of the plaintiffs until the U.S. Supreme Court decides whether to hear another case on the underlying antitrust issue.
September 08, 2011
A Pennsylvania federal judge on Thursday approved the dismissal of health insurer AvMed Inc.'s antitrust claims from consolidated class action litigation against Cephalon Inc. and generics makers over an alleged conspiracy to keep narcolepsy drug Provigil off the market.